Therapeutic Opportunities in Microplastic- and Nanoplastic-Associated Neuroinflammation: A Mechanism-Guided Analysis of Drug Development, Repurposing, and New-Indication Opportunities
This paper is also available at:
Microplastics and nanoplastics (MPs/NPs) can interact with biological systems through multiple mechanisms that may affect the central nervous system, including immune activation, blood-brain barrier dysfunction, oxidative stress, mitochondrial dysfunction, cytokine signaling, disrupted autophagy/proteostasis, neuronal injury, and gut-brain axis disruption. These pathways are biologically plausible, but links to human disease remain incomplete and require further study.
From a therapeutic-development perspective, the key question is whether characterizing MP/NP-associated pathology can reveal actionable biological pathways. This creates opportunities for novel targets (where coverage is limited), drug repurposing (where existing agents already target the pathway), and indication expansion (where MP/NP-derived insights apply to other diseases sharing the same pathway).
We outline a preliminary mechanism-guided landscape of MP/NP-associated neuroinflammatory biology and a framework for identifying these opportunities. Based on this analysis, Cythera Bio has prioritized two pathways for initial investigation, with others still under evaluation.
Figure 1. Therapeutic opportunity landscape for MP/NP-associated neuroinflammation.
1. Introduction
Research into the biological effects of MPs/NPs has expanded from environmental toxicology toward questions of human exposure, tissue distribution, cellular interactions, and potential health effects.
The nervous system represents a particularly important area of investigation. Recent literature describes evidence and mechanistic hypotheses involving brain accumulation and transport, blood-brain barrier interactions, oxidative stress, mitochondrial dysfunction, inflammatory signaling, synaptic effects, autophagy, and gut-brain communication. At the same time, significant uncertainty remains regarding exposure-response relationships, environmentally relevant concentrations, polymer and particle heterogeneity, chronic exposure, and translation from experimental systems to human disease.
This uncertainty should distinguish mechanistic hypothesis generation from clinical causality. Evidence that MPs/NPs activate a pathway experimentally does not establish that MP/NP exposure causes a particular neurological disease in humans.
However, the emerging mechanistic literature creates another question that can be investigated independently:
If MPs/NPs produce a reproducible pathological phenotype, can the mechanisms underlying that phenotype reveal actionable therapeutic opportunities?
This paper examines that question in the context of neuroinflammation.
Figure 2. Conceptual framework for MP/NP-associated neuroinflammatory pathology.
2. Neuroinflammation as a Multi-Mechanism Process
Neuroinflammation does not represent a single molecular pathway. It emerges through interactions among immune cells, glial cells, vascular and barrier systems, neurons, cellular metabolism, and systemic inflammatory signals.
Similarly, MP/NP-associated neurotoxicity appears unlikely to be explained by one mechanism. Recent reviews describe convergent experimental evidence involving oxidative stress, inflammatory signaling, mitochondrial dysfunction, neurotransmitter and synaptic effects, and BBB perturbation.
A mechanism-guided analysis therefore provides a useful alternative to treating "MP/NP neurotoxicity" as a single therapeutic target.
Representative Mechanistic Landscape
Pathway / Process | Key Pathology Features | Plausible MP/NP Contribution | Preliminary Priority |
Microglial / innate immune activation | Pro-inflammatory phenotype; cytokine release | Particle uptake and inflammatory signaling, including TLR/NF-κB-associated mechanisms | High |
BBB integrity | Tight-junction loss; increased permeability | Endothelial oxidative stress, cellular injury and altered barrier integrity | High |
Oxidative stress / ROS | Lipid peroxidation; cellular and DNA damage | Particle-associated cellular stress and mitochondrial ROS | High |
Mitochondrial dysfunction | Impaired bioenergetics; altered mitochondrial homeostasis | Mitochondrial interactions, membrane dysfunction and oxidative stress | High |
Cytokine / inflammasome signaling | IL-1β, TNF-α, IL-6 and related inflammatory signaling | Activation of inflammatory pathways including NLRP3/NF-κB in experimental systems | High–Moderate |
Autophagy / proteostasis | Impaired cellular clearance and aggregate handling | Altered autophagic flux, lysosomal biology and particle-associated cellular stress | Moderate–High |
Synaptic / neuronal integrity | Synaptic dysfunction and neuronal injury | Downstream inflammatory, mitochondrial and cellular effects | Moderate |
Gut-brain axis | Systemic inflammatory signaling and neuroimmune effects | Dysbiosis, intestinal barrier effects and altered gut-brain signaling | Moderate |
These categories are intended to organize research hypotheses rather than establish validated clinical effects.
Experimental work continues to strengthen several of these mechanistic links. For example, recent animal research has reported MP-associated microglial and astrocytic activation, NLRP3 activation, mitochondrial and synaptic injury in Alzheimer's disease models. Other recent work has connected MPs with impaired autophagic flux, gut microbiome changes and worsening pathology in an Alzheimer's model.
3. Blood-Brain Barrier and Neurovascular Biology
The blood-brain barrier represents both a potential route of CNS exposure and a biological system that may itself be affected by MP/NP-associated processes.
Experimental and translational literature suggests that particle size, surface characteristics, barrier condition, and other variables influence CNS entry. Human CSF research has detected selected polymer types and reported relationships between some particle concentrations and measures of BBB impairment, although that study did not find a significant association between MNP concentrations and CSF IL-6 or IL-8.
This distinction is important therapeutically. The relevant opportunity may not simply be preventing particles from crossing a barrier. It could include:
preserving endothelial function;
maintaining tight-junction integrity;
reducing particle-associated vascular inflammation;
restoring compromised neurovascular barriers; or
intervening in downstream pathology resulting from barrier dysfunction.
Thus, BBB biology may represent both an exposure mechanism and a therapeutic target.
4. Mitochondrial Dysfunction and Oxidative Stress
Mitochondrial effects represent another potentially important intersection between MP/NP toxicology and established therapeutic biology.
Recent literature describes NP-associated mitochondrial membrane depolarization, altered electron-transport activity, excessive ROS production, calcium dysregulation, changes in mitochondrial dynamics and downstream cellular injury.
Importantly, mitochondrial biology is already therapeutically actionable. In September 2025, the FDA granted accelerated approval to elamipretide (Forzinity) for Barth syndrome, a rare mitochondrial disorder.
This does not imply that elamipretide treats MP/NP-associated pathology. Rather, it illustrates a broader drug-development principle: a biological mechanism implicated in MP/NP-associated pathology may already have therapeutic precedent in another disease. That creates an opportunity to distinguish between target discovery and indication discovery.
5. Inflammatory and Inflammasome Signaling
MP/NP exposure has also been associated experimentally with inflammatory pathways involving microglial activation, NF-κB signaling, inflammasome activity, and inflammatory cytokines.
Many downstream inflammatory pathways are already extensively drugged.
At first glance, this could make such pathways appear less attractive for novel drug discovery. However, existing therapeutic coverage can create a different opportunity. If an established pathway can be shown to play a functionally important role in MP/NP-associated pathology, an existing therapeutic targeting that pathway could become a candidate for investigation in a new biological context or indication.
The relevant sequence is therefore:
Figure 3. From MP/NP pathology to new-indication opportunity.
This distinction is important. Detection of an inflammatory biomarker alone is insufficient to establish a therapeutic opportunity. Stronger evidence would demonstrate that the pathway contributes materially to the phenotype and that pathway modulation alters the resulting pathology.
6. Autophagy, Proteostasis and Cellular Clearance
MP/NP-associated effects on autophagy, lysosomal function and proteostasis may provide another bridge between exposure biology and established neurodegenerative mechanisms. Recent experimental work has reported impaired autophagic flux in association with chronic MP exposure in an Alzheimer's disease model. Broader reviews also identify autophagy and organelle communication as potential components of MNP-associated cellular dysfunction.
This area may be particularly relevant because impaired cellular clearance is already implicated across multiple neurological diseases.
The therapeutic question therefore extends beyond removing or neutralizing a particle:
Can cellular processes disrupted during MP/NP exposure be restored pharmacologically?
If so, the same intervention may potentially have relevance wherever similar cellular-clearance pathology occurs.
7. Gut-Brain Axis
MP/NP neurobiology may also involve mechanisms outside the CNS. Experimental evidence suggests that MNP exposure can alter intestinal barrier function, microbiome composition, inflammatory signaling and gut-brain communication.
A 2023 mouse study, for example, implicated gut-brain-axis and circadian-related pathways in polystyrene NP-associated neurotoxicity. More recent literature continues to describe gut-barrier disruption, dysbiosis, systemic inflammatory signaling and CNS effects as interconnected mechanisms.
This raises therapeutic possibilities involving not only CNS-directed interventions but potentially intestinal barrier biology, microbiome-derived signaling, systemic inflammation and other upstream mechanisms.
8. Mapping Existing Therapeutic Coverage
A mechanism becomes commercially and translationally interesting for different reasons depending upon existing therapeutic coverage. We propose four broad categories.
Mechanistic Situation | Therapeutic Opportunity |
Established pathway with approved therapeutics | Potential repurposing or new-indication opportunity |
Established pathway with clinical-stage therapeutics | Potential indication expansion or partnering opportunity |
Biologically important pathway with inadequate therapeutic coverage | Novel asset-development opportunity |
MP/NP-specific or poorly characterized mechanism | Novel target and therapeutic-discovery opportunity |
Consequently, a pathway should not automatically receive lower priority simply because drugs already exist against it.
In some cases, extensive pharmaceutical validation may make that pathway more attractive because target biology, pharmacology, manufacturing, safety experience and clinical-development precedent already exist.
The scientific challenge shifts from proving that the target is druggable to determining whether that target is meaningfully involved in the newly proposed pathology.
Figure 1. Therapeutic opportunity landscape for MP/NP-associated neuroinflammation.
9. The Bidirectional Indication Opportunity
The relationship between MP/NP research and pharmaceutical development can operate in both directions.
Direction 1: Existing Therapeutic → MP/NP-Associated Pathology
If an existing drug targets a mechanism demonstrated to be functionally important in MP/NP-associated pathology, that drug may warrant investigation for an additional indication.
This can be represented as:
Existing drug → validated mechanism → newly characterized MP/NP-associated pathology → potential new indication
Direction 2: MP/NP Research → Therapeutic Discovery → Broader Disease
The reverse may be equally important. An intervention discovered because it reverses MP/NP-associated pathology may act on a mechanism shared by established neurological diseases.
The pathway then becomes:
MP/NP-associated phenotype → therapeutic discovery → mechanism validation → other diseases sharing the mechanism → potential additional indications
Figure 4. Bidirectional therapeutic translation from MP/NP-associated pathology.
Other Diseases Sharing the Pathway
This framework means that the potential value of MP/NP therapeutic research is not necessarily limited to an eventual clinical category defined specifically by plastic exposure.
10. Broader Neurological Relevance
Many of the biological processes under investigation in MP/NP research overlap with mechanisms studied in established neurological disorders. Recent reviews discuss mechanistic intersections with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cerebrovascular disease and other neurological conditions, while appropriately emphasizing that mechanistic overlap does not establish that MNP exposure causes these diseases.
This distinction creates an important translational opportunity. A therapeutic program can originate from an exposure-associated experimental phenotype while ultimately identifying an intervention whose utility extends beyond that original context. Similarly, an established neurological therapeutic may warrant investigation in MP/NP-associated pathology when the relevant mechanism is demonstrated experimentally.
11. A Mechanism-Guided Therapeutic Development Framework
The approach described here can be organized into a sequential research workflow:
Characterize MP/NP-associated biological phenotypes.
Identify biological mechanisms contributing to those phenotypes.
Determine whether the relationship is correlative or functionally important.
Map existing drugs and development-stage assets against each pathway.
Identify pathways with limited therapeutic coverage.
Identify existing drugs or targets that could support new-indication hypotheses.
Experimentally evaluate pathway modulation.
Prioritize opportunities for therapeutic development.
Evaluate whether discoveries have relevance to additional diseases sharing the same pathology.
This approach separates three questions that are sometimes conflated:
What does MP/NP exposure do biologically?
Which of those biological effects are therapeutically actionable?
Which actionable opportunities are sufficiently compelling to develop clinically?
Figure 5. Mechanism-guided MP/NP therapeutic discovery workflow.
12. Translational Limitations
The field remains early. A substantial proportion of the mechanistic evidence concerning MP/NP neurobiology derives from cell culture and animal studies. Experimental particles, concentrations, exposure durations, surface chemistry and polymer composition vary considerably between studies. Human exposure and tissue measurements remain methodologically challenging.
Recent reviews specifically identify methodological heterogeneity, limited longitudinal human evidence and difficulties translating experimental exposure models into human disease risk.
Accordingly, several distinctions are essential:
Association is not causation. Pathway activation is not equivalent to disease causation.
A drug targeting an implicated pathway cannot be assumed to treat MP/NP-associated pathology. Mechanistic overlap with another disease does not establish that MPs/NPs cause that disease.
These uncertainties are precisely why controlled mechanistic experiments and therapeutic perturbation studies are important.
13. Initial Therapeutic Prioritization
The preliminary landscape presented here identifies multiple potential therapeutic opportunities across MP/NP-associated neuroinflammatory biology. These opportunities differ substantially in maturity. Some pathways already have extensive pharmaceutical validation and therefore may provide opportunities for drug repurposing or indication expansion. Others have emerging therapeutic programs but limited clinical validation. Still others remain comparatively under-addressed and may provide opportunities for novel therapeutic development.
Based on this preliminary analysis together with additional scientific and translational considerations, Cythera Bio has prioritized two of these pathways for initial therapeutic investigation.
The specific pathways and associated development programs are not disclosed in this paper.
Importantly, prioritization of two initial pathways does not imply that the remaining mechanisms lack therapeutic value. Several additional opportunities identified through this analysis warrant continued investigation as the underlying MP/NP biological literature and experimental evidence develop.
Furthermore, the biological pathways considered here are not unique to MP/NP-associated pathology. Many participate in neurological, inflammatory, metabolic and degenerative diseases more broadly.
Consequently, therapeutics identified through MP/NP-focused research may ultimately have potential applications across other clinical indications characterized by the same underlying pathology.
14. Conclusions
MP/NP therapeutic research may represent a broader drug-discovery opportunity than the development of interventions directed specifically at the particles themselves.
Emerging experimental literature implicates multiple interacting biological processes in MP/NP-associated neurotoxicity and neuroinflammation, including microglial activation, neurovascular and blood-brain barrier dysfunction, oxidative stress, mitochondrial dysfunction, inflammatory and inflammasome signaling, autophagy and proteostasis, neuronal injury, and gut-brain-axis effects.
Mapping this biology against the existing pharmaceutical landscape creates at least two complementary opportunities.
First, established drugs and drug targets may acquire potential new indications when their mechanisms are demonstrated to play a meaningful role in MP/NP-associated pathology.
Second, novel therapeutics discovered through MP/NP-associated pathology may have applications beyond MP/NP exposure when the targeted mechanism is shared by other diseases.
Cythera Bio has prioritized two pathways from the initial neuroinflammatory landscape for further therapeutic investigation while continuing to evaluate additional opportunities.
This paper represents the first analysis in a broader series examining the therapeutic implications of MP/NP-associated biology.
Future analyses will examine additional organ systems and pathological processes, including gastrointestinal and microbiome-associated biology, chronic inflammatory pathways, and other areas in which MP/NP-associated mechanisms may reveal opportunities for novel drug development, therapeutic repurposing, and indication expansion.
Disclaimer
This paper presents a research and therapeutic-development framework based on emerging scientific literature. It is intended for scientific discussion and hypothesis generation and does not establish that microplastics or nanoplastics cause any specific human disease. References to existing or investigational therapeutics do not constitute evidence of efficacy for MP/NP-associated pathology, treatment recommendations, or clinical guidance. Proposed therapeutic opportunities require experimental validation and, where applicable, appropriate preclinical and clinical investigation.
Comments